•
Jun 30, 2021
Onconova Q2 2021 Earnings Report
Reported financial results for the second quarter of 2021 and provided a business update.
Key Takeaways
Onconova Therapeutics reported a net loss of $4.2 million, or $0.27 per share, for the second quarter of 2021. As of June 30, 2021, cash and cash equivalents were $43.7 million.
Initiated U.S. Phase 1 study of ON 123300 and opened enrollment to the second cohort.
Partner HanX Biopharmaceuticals is enrolling to the third dose cohort of the complementary Phase 1 study in China.
Reported encouraging preliminary results from the investigator-initiated study evaluating rigosertib plus nivolumab in advanced KRAS-mutated NSCLC.
Company believes that its cash and cash equivalents will be sufficient to fund ongoing clinical trials and business operations for more than eighteen months.